- Lobbying
- allergan
Lobbying Arrangements Results for 'Allergan'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Health care Products |
Allergan
|
Platinum Advisors, LLC | |||
Details FDA Issues |
ALLERGAN, INC.
|
Pacific Consulting Associates, Inc. | |||
Details S.1948, a bill to abrogate the sovereign immunity of Indian tribes. |
Allergan USA, Inc.
|
Sixkiller Consulting, LLC | |||
Details Medicare Parts B and D drugs payments and access. |
ALLERGAN, INC.
|
THE MCMANUS GROUP | |||
Details GENERAL DISCUSSIONS RELATED TO THE SECURITIES AND EXCHANGE COMMISSION'S POLICIES ON FRAUD/INSIDER TRADING GENERAL ISSUES RELATED TO THE HOSTILE ACQUISITION ATTEMPT ON ALLERGAN, INC. |
ALLERGAN, INC.
|
in-house lobbying | |||
Details Health reform issues |
Allergan, Inc.
|
Trimpa Group LLC | |||
Details Proposals to maintain and strengthen intellectual property protections to incentivize research and development of novel, new life-saving therapies to meet unmet medical needs; proposals to modify t... |
Allergan USA, Inc.
|
J P Ford Strategies, LLC | |||
Details Medical Device Regulation & Legislation |
Allergan, Inc.
|
Mr. Dan Cohen | |||
Details Follow-on biologics, drug re-importation, public health aspects of select agents |
Allergan
|
HPS Group, LLC (formerly Steven Grossman) | |||
Details Animal enterprise terrorism legislation; NIH funding |
Allergan, Inc.
Specialty pharmaceutical company |
King & Spalding LLP | |||
Details Medicare and Medicaid reimbursement |
Allergan Inc.
Biotechnology and specialty pharmaceutical product manufacturer |
THE MCMANUS GROUP | |||
Details Issues related to support for research and development. Issues related to corporate tax reform; antitrust regulation. |
Allergan, Inc.
|
BAKER & HOSTETLER LLP | |||
Details Securities Law Disclosures Corporate Tax Reform Antitrust Review |
Allergan, Inc.
|
CYPRESS ADVOCACY, LLC | |||
Details Issues related to corporate tax reform. Issues related to pharmaceutical reimbursement; issues related to intellectual property and drug counterfeiting; issues related to Restastis. |
Allergan, Inc.
|
Jake Perry + Partners | |||
Details Medicare Part B Drug Coding |
ALLERGAN, INC.
|
BUCHANAN INGERSOLL & ROONEY PC | |||
Details Issues related to patent reform Issues related to Medicare Part B and Part D |
ALLERGAN, INC
|
JEFFREY J. KIMBELL AND ASSOCIATES | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act. |
Allergan, Plc.
Allergan is a diversified global pharmaceutical company |
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details public health issues impacting pharmaceuticals; Select Agent Program and Biosafety Improvement Act of 2008 |
Allergan
|
MCKENNA, LONG & ALDRIDGE | |||
Details Issues related to obesity intervention; issues related to drug approval. Issues related to pharmaceutical reimbursement; Issues related to intellectual property and drug counterfeiting; Issues rela... |
Allergan USA, Inc.
|
CAUTHEN FORBES & WILLIAMS | |||
Details Discussions concerning the portion of the Health Care Bill (including HR 3962) that creates an additional fee for discretionary cosmetic surgery. |
Allergan, Inc.
|
Dutko Worldwide, LLC d/b/a Grayling | |||
Details Issues related to coverage for bariatric services in the essential health benefits package pursuant to the Affordable Care Act, FDA enforcement of the Food, Drug and Cosmetic Act and the promotion ... |
Allergan, Inc.
|
Thorn Run Partners | |||
Details The merger between Pfizer and Allergan, and related competition issues. |
Pfizer Inc.
|
Bloom Strategic Counsel | |||
Details Issues related to drug approval. Issues related to FDA draft guidances. Issues related to pharmaceutical reimbursement; issues related to intellectual property and drug counterfeiting; issues relat... |
Allergan USA, Inc.
|
Forbes-Tate | |||
Details Treatment of drugs and biologics under the hospital outpatient rule and other CMS rulemaking |
ALLERGAN
|
HILLCO PARTNERS | |||
Details Issues related to corporate tax reform. Issues related to pharmaceutical reimbursement; issues related to intellectual property and drug counterfeiting; issues related to Restastis. |
Allergan, Inc.
|
Crossroads Strategies, LLC | |||
Details Health Issues; Obesity |
Allergan
Health Care |
MS&L | |||
Details Issues related to obesity intervention; issues related to drug approval. Issues related to pharmaceutical reimbursement; issues related to intellectual property and drug counterfeiting; issues rela... |
Cauthen Forbes & Williams on behalf of Allergan USA, Inc.
|
Forbes-Tate | |||
Details FDA approval process as related to medical devices. |
Dan Cohen Consultants
Specialty pharmaceutical and medical device company. |
JOHNSON, MADIGAN, PECK, BOLAND & STEWART, INC. | |||
Details Monitor, advise, and as appropriate directly advocate on healthcare and tax policy issues related to Allergan specifically and the lifesciences industry generally. |
Allergan, Inc.
|
Barbour Griffith & Rogers, LLC d/b/a BGR Holding | |||
Details Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act whi... |
Allergan USA, Inc.
|
in-house lobbying | |||
Details Medicare coverage and reimbursement |
The McManus Group on behalf of Caris Life Sciences and Breathe Technologies Inc.
Government affairs consulting |
WALTER CONSULTING | |||
Details Abuse deterrent formulations Trans-Pacific Partnership (TPP) intellectual property protection and policy |
Allergan plc
|
Arent Fox LLP | |||
Details Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R.... |
Allergan, plc (formerly known as Actavis)
|
Van Heuvelen Strategies, LLC | |||
Details Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation. |
Allergan, Inc.
pharmaceutical, biological and medical device manufacturer |
MCDERMOTT WILL & EMERY LLP | |||
Details DOJ policy regarding off label communications. |
Medical Information Working Group
|
SIDLEY AUSTIN LLP | |||
Details Antitrust issues associated with proposed merger between Pfizer and Allergan |
PFIZER, INC
Pharmaceutical corporation |
BROWNSTEIN HYATT FARBER SCHRECK, LLP | |||
Details Enforcement priorities and policies regarding communications by pharmaceutical and medical device manufacturers about their medical products. |
Medical Information Working Group
|
Ropes & Gray, LLP | |||
Details Worked on industry concerns related to S. 2543, the Prescription Drug Pricing Reduction Act (PDPRA) of 2019; S.1895, the Lower Health Care Costs Act; and S. 3129 and HR 19, the Lower Costs, More Cu... |
Allergan, Inc. (formerly Actavis, Inc.)
|
The D Major Group |